ABSTRACTr Twelve patients with chronic asthma received either high dose beclomethasone once a day or standard doses of beclomethasone three times a day in a double blind crossover trial to determine whether inhalation once a day would be sufficient. With the once a day regimen peak expiratory flow rates fell significantly, symptoms of nocturnal asthma increased, and two patients withdrew from the study because of worsening asthma. Whether control can be achieved with steroids inhaled once a day by simply increasing the total daily dose remains to be seen.
Inhaled corticosteroids used in treating chronic asthma are usually given three or four times daily,' but recently it has been shown that twice daily regimens may also be effective.23 To see whether inhalation once a day would be sufficient we ( or placebo) was given in three or four divided daily doses as usual and the total daily dose was not changed. The dosage of once daily, high dose beclomethasone (or placebo) was calculated as follows: 4-6 puffs standard beclomethasone/day (200-300 ug) = 1 puff high dose (250 ,ug); 7-10 puffs standard beclomethasone/day (350-500 ,ug) = 2 puffs high dose (500 ,ug); 11 and 12 puffs standard beclomethasone/day (550 and 600 ,g) = 3 puffs high dose (750 ,ug). Inhaled or oral bronchodilators were taken as usual.
The patients kept a diary and recorded scores for daytime and nocturnal symptoms and peak expiratory flow rate (PEFR). To check compliance with treatment doses of all drugs used were also recorded. Symptoms of daytime wheeze, shortness of breath, and nocturnal asthma were scored by the patients as none (0), mild (1) 
STATISTICAL ANALYSIS
During each period mean scores for symptoms and peak expiratory flow rate were calculated, and these were compared using a paired t test. To allow for a possible "carry over" effect after changing regimens data for the first 10 days of each four week period were not analysed.
Results
Two patients withdrew from the study because of increasing asthma seven and 10 days after starting the once daily regimen. In the remaining 10 patients there was no difference in scores for symptoms and peak expiratory flow rate between the run in period
Discussion
Two studies have shown that inhaled corticosteroids given twice daily produce satisfactory control of asthma.23 In our study, however, beclomethasone inhaled once a day was less effective than an equivalent amount given in three or four divided doses. Peak expiratory flow rate fell significantly, symptoms of nocturnal asthma increased, and two patients withdrew because of worsening asthma when patients were changed to a once daily regimen. Although shortness of breath and daytime wheeze also increased, these just failed to achieve significance, possibly because patients found these symptoms more difficult to measure.
We elected to given once daily treatment from a high dose beclomethasone inhaler rather than by multiple inhalations from a standard dose inhaler because this would be a more convenient and practical method for the patient. Although this meant that an identical dose of beclomethasone was not given in the two periods of treatment, the dose conversion we used ensured that in all but one of the patients the once daily dose was somewhat higher. Deterioration while receiving once daily treatment was thus not due to a reduction in the effective daily dose.
In contrast with these findings with inhaled corticosteroids, patients taking oral corticosteroids are usually satisfactorily controlled with once daily or alternate day dosage. Whether control can be achieved with once daily inhaled steroids by simply increasing the total daily dose remains to be seen.
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